| Name | Title | Contact Details |
|---|---|---|
Rose Huddleston |
Chief People Officer | Profile |
Ophelia is a digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD), committed to making evidence-based treatment universally accessible. Its mission is to remove barriers for the 80% of Americans with OUD who are unable to access care and the 50,000+ MAT-licensed clinicians who are unable to treat patients due to a lack of infrastructure, training, and support. At its core is the Ophelia Care Model, a team-based clinical model and software platform developed by leading experts in addiction medicine and psychiatry. Ophelia is licensed to provide care in 36 states and contracted with Medicaid, Medicare, and Commercial insurers covering 85 million American lives.
Nexus operates 6 residential treatment sites with programming accredited by COA or TJC, and year-round, on-site schools, as well as inpatient psychiatric care programs, foster care and adoption, in-home counseling services, and ongoing support. Our programs offer a continuum of services to provide boys and girls a safe place to face their past and begin their future. We operate sites and services in Minnesota, Illinois, Maryland, North Dakota, and Idaho, each offering specialized treatment options for your child`s or adolescent`s needs. Mille Lacs Academy Gerard Academy Nexus Glen Lake Indian Oaks Academy Onarga Academy Woodbourne Center Kindred Family Focus PATH North Dakota PATH Idaho
CRH Healthcare is a patient and quality focused urgent care center company focused on delivering the Perfect Patient Experience every time.
Morningside Manor Inc is a Alcester, SD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.